Announcements Trials
Browse Landscape

Phase

Phase 2 114Phase 1 51Phase 3 34Phase 1/2 30Phase NA 5Phase 2/3 4Phase EARLY_PHASE1 2Phase 4 2

Status

Unknown 2Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 4CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Meningeal Carcinomatosis 1

Interventions

Exercise 439Blood Specimen Collection 333Standard of Care 321Magnetic Resonance Spectroscopy 259Radiotherapy 255Surveys and Questionnaires 245Radiosurgery 245Educational Status 230Methods 229Early Intervention, Educational 218Practice Guidelines as Topic 146Interviews as Topic 146Biopsy 146Surgical Procedures, Operative 135Drug Therapy 133Control Groups 128Acupuncture Therapy 124Therapeutics 110Cyclophosphamide 103Palliative Care 101Counseling 101Resistance Training 95Saline Solution 90Cisplatin 90Magnetic Resonance Imaging 89Radiofrequency Ablation 86Specimen Handling 79Radiotherapy, Intensity-Modulated 79Colonoscopy 79Cognitive Behavioral Therapy 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase NA × osimertinib × Clear all
NCT03969823 2026-04-24

Whole Genomic Landscape of Advanced EGFR-mutant NSCLC

Seoul National University Hospital

Phase NA Active not recruiting
148 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06304441 2025-09-29

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Guangzhou Medical University

Phase NA Recruiting
100 enrolled
CNS

Meningeal Carcinomatosis

NCT06709274 2024-11-29

MOTION-NSCLC

Guangdong Association of Clinical Trials

Phase NA Not yet recruiting
342 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05583409 2022-10-17

SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC

Tongji Hospital

Phase NA Unknown
72 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04816838 2021-08-25

A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations

Yonsei University

Phase NA Unknown
25 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡